Hugues de Lavallade

6PUBLICATIONS
40CO-AUTHORS
Predictive and prognostic markersHaematologyEpidemiological modellingMedical virologyTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jul 24, 2026
Five-year follow-up of OPTIC: long-term efficacy, safety, and mutation analyses of ponatinib in chronic-phase chronic myeloid leukemia from a randomized phase 2 trial.

|Apr 10, 2026
Management of tyrosine kinase inhibitors and donor lymphocyte infusions post transplantation for chronic myeloid leukemia: a survey of contemporary practice on behalf of the chronic malignancies working party of the EBMT.

Alexandros Kanellopoulos, Linda Koster, Hugues de Lavallade

|Jul 24, 2025
QRISK3 score is predictive of thrombotic risk in patients with myeloproliferative neoplasms.

Andrea Duminuco, Raj Vaghela, Sukhraj Virdee

|Sep 09, 2022
Third-dose SARS-CoV-2 mRNA vaccine increases Omicron variant neutralization in patients with chronic myeloid disorders.

Patrick Harrington, Ashwini Kurshan, Marc Delord

|Apr 23, 2022
Impaired humoral and T cell response to vaccination against SARS-CoV-2 in chronic myeloproliferative neoplasm patients treated with ruxolitinib.

Patrick Harrington, Katie J Doores, Jamie Saunders

|Jun 04, 2021
Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia.

Patrick Harrington, Katie J Doores, Deepti Radia

Pageof 1

Frequent Collaborators

4 joint publications

Patrick Harrington

3 joint publications

Donal P McLornan

2 joint publications

Jamie Saunders

2 joint publications

Thomas Lechmere